Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTekCapital Regulatory News (TEK)

Share Price Information for TekCapital (TEK)

Share Price is delayed by 15 minutes
Get Live Data
5.80    -0.10 (-1.69%)
Bid:
5.70
Ask:
5.90
Spread: 0.20 (3.509%)
Market Cap: £14.92m
TEK Live PriceLast checked at - London Stock Exchange

Intraday TekCapital Share Chart

$0.35m Contract Win

20 Mar 2025 07:00

RNS Number : 3785B
GenIP PLC
20 March 2025
 

 

 

20 March 2025 

 

GenIP Plc

("GenIP" or the "Company")

 

$0.35m Contract Win

 

GenIP Plc, a technology business providing Generative Artificial Intelligence (GenAI) services to help research organisations and corporations commercialise their innovations, is pleased to announce it has secured a significant contract worth $0.35m with a new client, a research organisation in Saudi Arabia (the "Client").

 

The contract commences immediately and covers the delivery of 400 GenAI-enhanced analytical assessments and additional technology commercialisation consulting services.

 

Analytical assessment revenue will be recognised upon report production by GenIP and delivery to the Client.

 

Melissa Cruz, CEO of GenIP, commented:

 

"We are delighted to announce this contract with a new client based in the Kingdom of Saudi Arabia. This agreement highlights the expanding range of services GenIP offers to global research organizations looking to accelerate the commercialization of their technological discoveries. We look forward to continuing to deliver value to our clients and will provide updates on significant developments as they arise."

 

For further information regarding GenIP, please visit www.genip.ai, or contact:

 

GenIP Plc

Melissa Cruz, CEO 

Via Redchurch Communications

Beaumont Cornish Limited (Nominated Adviser)

Roland Cornish / Asia Szusciak / Andrew Price

 

 

Tel: +44 (0) 20 7628 3396

 

Novum Securities Limited (Broker) 

Jon Belliss

Tel: +44 (0)20 7399 9425

JBelliss@novumsecurities.com

 

 

Redchurch Communications (Financial PR)

John Casey

 

 

genip@weareredchurch.com

 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.

 

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

 

Notes to Editors

 

About GenIP

 

GenIP provides generative artificial intelligence (GenAI) analytic services to help companies, research institutions and venture funds assess and commercialise new discoveries. GenIP combines expert human technical review with GenAI algorithms to provide insightful and verified services.

 

GenIP provides two complementary platform-based services:

1. Invention Evaluator: Provides bespoke research reports that assess the market potential of new technological innovations and discoveries using AI-driven proprietary software; and

 

2. Vortechs: which is an executive recruitment platform that through advanced machine learning algorithms and natural language processing technologies assists in matching technology organisations with experienced executives skilled in technology commercialisation.

 

The Company believes that its integrated GenAI service offerings will help organisations to evaluate and commercialise their technological innovations. 

Company Strategy

GenIP's goal is to be a leading Generative AI analytic services company. To achieve this, the Company has established three strategic pillars:

 

Organically grow Invention Evaluator and Vortechs' revenue through institutional and corporate connections as well as increase client pipeline through marketing, advertising and social media spend.

Expand the Generative AI service offerings within Invention Evaluator and Vortechs' to reach new customers and improve margins.

Bolt-on acquisitions of additional Generative AI services that are helpful to our clients and have demonstrated initial market traction. 

 

 

Forward looking statements

 

Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.

 

Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".

 

For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.

-ENDS-

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTGPUUCWUPAGRB
Date   Source Headline
10th Apr 20257:00 amRNS-RInnovative Eyewear Receives EU Certification
31st Mar 20255:34 pmRNSUnaudited Results to 31 December 2024
20th Mar 20257:00 amRNS$0.35m Contract Win
13th Mar 20257:00 amRNSCorporate Update & 2025 Outlook
17th Feb 20257:00 amRNS2024 Review - Year End Portfolio Update
14th Feb 20251:22 pmRNSNotification of Major Holdings
3rd Feb 20257:00 amRNSOversubscribed Fundraising of £2.3Million
30th Jan 20257:00 amRNS-RInnovative Eyewear announces Key Partnership
22nd Jan 202511:14 amRNSNotification of Major Holdings
21st Jan 20257:00 amRNSGuident Receives Significant New Patent Coverage
17th Jan 20259:13 amRNSPlacing of £0.5 million (c.$0.6m)
15th Jan 20257:00 amRNSGuident Corp. Appointment of Investment Banker
20th Dec 20247:00 amRNSPortfolio Company Update - Guident Ltd
4th Dec 20247:00 amRNSIssue of Shares to Advisers
25th Nov 20249:13 amRNS-RPortfolio Company Update - Innovative Eyewear
20th Nov 20244:26 pmRNSNotification of Major Holdings
20th Nov 20247:00 amRNSCorporate Update
15th Nov 20247:00 amRNSFundraising of £1.0 Million
30th Oct 20247:00 amRNSNew and Follow-on B2B Customer Orders
8th Oct 20247:00 amRNSCorporate Update
2nd Oct 20248:00 amRNSTekcapital Spins out GenIP onto AIM
25th Sep 20247:00 amRNSHalf Year Results
18th Sep 20247:58 amRNSGenIP plc Schedule One
16th Sep 20247:00 amRNSMultiple Placements of Products and B2B Progress
13th Sep 20241:37 pmRNSHolding(s) in Company
29th Aug 20247:00 amRNSPortfolio Company Update Innovative Eyewear Inc
13th Aug 20247:00 amRNSInnovative Eyewear 2nd Q24 Revenue increased 82%
1st Jul 202411:21 amRNSGrant of Share Options
21st Jun 20244:20 pmRNSResults of Annual General Meeting
30th May 20247:00 amRNSPortfolio Company Update - Innovative Eyewear
22nd May 20247:00 amRNSFinal Results year ended 31 December 2023
2nd May 20247:00 amRNSPortfolio Company Update Guident Q1 2024
26th Apr 20247:00 amRNSInnovative Eyewear Canadian Partnership
25th Apr 20247:00 amRNSInnovative Eyewear Patent Filings
18th Apr 20247:00 amRNSInnovative Eyewear Signs Brand Ambassador
17th Apr 20247:00 amRNSInnovative Eyewear Distribution Partnership
9th Apr 20247:00 amRNSPortfolio Company Update : Guident Ltd
5th Apr 20247:00 amRNSPortfolio Company Update : Guident Ltd
28th Mar 202410:20 amRNSNotification of Major Holdings
7th Mar 202411:15 amRNSNotification of Major Holdings
6th Mar 20247:00 amRNSIntellectual Property Update
29th Feb 20247:51 amRNSFundraising of £2.0 million
19th Feb 20247:00 amRNSPortfolio Company Update : Guident Ltd
15th Feb 202410:31 amRNSNotification of Major Holdings
15th Feb 20247:00 amRNSGuident Expands its Strategic Partnership
13th Feb 20242:24 pmRNSNotification of Major Holdings
1st Feb 20247:15 amRNSMicroSalt Admission to AIM First Day of Dealings
1st Feb 20247:01 amRNSNotice of Presentation on Investor Meet Company
24th Jan 20247:00 amRNSBellescura Plc - Disposal of Shares
12th Jan 20244:31 pmRNSLoan Agreement with Innovative Eyewear Inc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.